Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators.
Marks
P A
PA
Program of Cell Biology and Genetics, DeWitt Wallace Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Richon
V M
VM
Rifkind
R A
RA
D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002453:Cell Cycle; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects*; D002461:Cell Line, Transformed / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D051379:Mice; D014407:Tumor Cells, Cultured
D000081:Acetamides; D016588:Anticarcinogenic Agents; D018797:Cell Cycle Proteins; C014026:hexamethylene bisacetamide